- 不限
- 2024-06-06 [星期四]
- 2024-06-07 [星期五]
- 2024-06-08 [星期六]
- 不限
- 沃森报告厅 Watson Auditorium
- EII 厅 Exhibition Area - II
- EIII 厅 Exhibition Area - III
- M1会议室 Meeting room - M1
- M2会议室 Meeting Room - M2
- M3会议室 Meeting Room - M3
- M4会议室 Meeing Room-M4
- M5会议室 Meeting Room - M5
- M9会议室 Meeting room - M9
2024-06-06 星期四
M1会议室 Meeting room - M1
2024-06-07 星期五
沃森报告厅 Watson Auditorium
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:20 |
Artificial intellgence enpowered thoracic surgery innovation |
Jian-Xing He | The First affiliated Hospital of Guangzhou Medical University, China |
| 08:20-08:40 |
Conventional transarterial chemoembolization for BCLC 0-A hepatocellular carcinoma |
Shiro Miyayama | Fukuiken Saiseikai Hospital, Japan |
| 08:40-09:00 |
Interventional thermal immuno-modulatory effects |
Lisa X. Xu | Shanghai Jiao Tong University, China |
| 09:00-09:20 |
Precision managing of lung cancer treatment |
Cai-Cun Zhou | Dongfang Hospital Affiliated to Tongji University, China |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:20 |
NIH projects on AI for medical imaging |
Krishna Kandarpa | National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, USA |
| 10:20-10:40 |
Thermal ablation for colorectal liver metastasis |
Kelvin Hong | Johns Hopkins University, USA |
| 10:40-11:00 |
Current status of TACE plus systemic therapy in HCC |
Gao-Jun Teng | Zhongda Hospital, Southeast University, China |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:00-11:20 |
Multidisciplinary management of liver cancer in the era of immunotherapy |
Chung Cheung Thomas Yau | University of Hong Kong, China |
| 11:20-11:40 |
Top oncology papers you should be aware of- an editor's choice |
Ziv J. Haskal | University of Virginia School of Medicine, USA |
| 11:40-12:00 |
Microbial cancer therapy: Bugs as drugs: The new opportunities for IR and medical imaging |
Xiaoming Yang | University of Washington School of Medicine, USA |
EII 厅 Exhibition Area - II
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 12:15-12:20 |
Opening Remarks
Gao-Jun Teng
Zhongda Hospital, Southeast University, China
|
||
| 12:20-12:25 |
Opening Remarks
Xiao-Li Zhu
The First Affiliated Hospital of Soochow University, China
|
||
| 12:25-12:45 |
Drug Resistance of Systematic Therapy for Advanced HCC and Follow-up Strategy |
Fei Gao | Sun Yat-Sen University Cancer Center, China |
| 12:45-13:05 |
Comprehensive consideration in clinical selection of anti-tumor drugs |
Xue-Feng Luo | West China Hospital, Sichuan University, China |
| 13:05-13:15 |
Summary
Long Jin
Beijing Friendship Hospital, Capital Medical University, China
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:50 |
Where the wild things are: searching for cryptic antigen peptides for tumor vaccine therapy |
Er-Wei Song | Sun Yat-sen Memorial Hospital Sun Yat-sen University, China |
| 13:50-14:02 |
Specifics of MWA for breast cancer |
Jie Yu | Chinese PLA General Hospital, China |
| 14:02-14:14 |
Chinese experience: da Vinci Robot in breast cancer surgery |
Ning Liao | Guangdong Provincial People's Hospital, China |
| 14:14-14:26 |
Transarterial chemoembolization for breast cancer |
Hai-Peng Yu | Tianjin Medical University Cancer Institute & Hospital, China |
| 14:26-14:40 |
Q ＆ A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:00-15:15 |
Cellular stress and tumor microenvironment remodeling |
Qiang Gao | Zhongshan Hospital Fudan University, China |
| 15:15-15:30 |
Integrating multidisciplinary teamwork for treatment of hepatocellular carcinoma |
Ming Kuang | The First Affiliated Hospital, Sun Yat-Sen University, China |
| 15:30-15:50 |
Q & A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:50-16:05 |
Molecular typing and precise treatment of triple-negative breast cancer |
Yi-Zhou Jiang | Fudan University Shanghai Cancer Center, China |
| 16:05-16:20 |
Androgens and cell fate determination |
Dong Gao | University of Chinese Academy of Sciences, China |
| 16:20-16:35 |
Discovery of Pl3K, past story and future development |
Jing Fan | The First Affiliated Hospital of PLA Air Force Medical University, China |
| 16:35-17:00 |
Q ＆ A
Qi Tang
Yunnan Cancer Hospital, China /
Jing Fan
The First Affiliated Hospital of PLA Air Force Medical University, China /
Shuang Wen
Yuxi People's Hospital, China
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 17:00-17:12 |
Intervention and outcomes of spine and sacral metastases |
Francis Y. Lee | Yale School of Medicine, USA |
| 17:12-17:24 |
Transarterial micro-embolization for MSK pain management |
Yi Zhang | Southeast University Affiliated Zhongda Hospital |
| 17:24-17:36 |
Cryoablatiin for soft tissue sarcoma in China: Technology and strategy |
Hai-Peng Yu | Tianjin Medical University Cancer Institute & Hospital, China |
| 17:36-17:50 |
Q ＆ A |
||
EIII 厅 Exhibition Area - III
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 12:15-12:20 |
Opening Remarks
Gao-Jun Teng
Zhongda Hospital, Southeast University, China
|
||
| 12:20-12:35 |
TACE with epirubicin-loaded microspheres for HCC: A prospective, single-arm, multicenter, phase 2 study (STOPPER trial) |
Hai-Dong Zhu | Zhongda Hospital, Southeast University, China |
| 12:35-12:45 |
Efficacy & Safety of TANDEM Microspheres in Super-selective Transarterial Chemoembolization |
David Hahn | |
| 12:45-12:55 |
Redefining the Precision Image-guided Solution for Interventional Oncology in Liver Cancer Treatment |
Simone Henrichs | |
| 12:55-13:15 |
Panel Discussion |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:42 |
MDT strategy for management of primary liver cancer |
Ming Kuang | The First Affiliated Hospital, Sun Yat-Sen University, China |
| 13:42-13:54 |
Personalized treatment for HCC – different tumors, different treatments |
Edward W. Lee | David Geffen School of Medicine at UCLA, USA |
| 13:54-14:06 |
Current status of HCC management in South Korea |
Hyun Ki Yoon | Asan Medical Center, University of Ulsan College of Medicine, Korea |
| 14:06-14:18 |
All about extrahepatic collaterals in TACE for HCCs |
Sangjoon Park | Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Korea |
| 14:18-14:30 |
Chinese Expert Consensus on Conversion and Perioperative Management of Hepatocellular Carcinoma(HCC) |
Jian Zhou | Zhongshan Hospital, Fudan University, China |
| 14:30-14:40 |
Q & A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 14:40-14:52 |
Pressure-enabled delivery and the future of locoregional immunotherapy |
Jon C. Davidson | University Hospitals Cleveland Medical Center, USA |
| 14:52-15:04 |
The dynamic of T cell responses correlated with the anti-PD-1 adjuvant therapy after RFA for patients with HCC |
Yong-Hong Zhang | Beijing YouAn Hospital, Capital Medical University, China |
| 15:04-15:16 |
Establishing and harmonizing systemic and locoregional therapy in HCC |
David M. Liu | Vancouver General Hospital, Canada |
| 15:16-15:28 |
Immunotherapy for hepatocellular carcinoma |
George Lau | Humanity and Health Medical Group, HKSAR, China |
| 15:28-15:40 |
The role of TACE vs DEB-TACE in treating HCC: Do we need elution? |
Ziv J. Haskal | University of Virginia School of Medicine, USA |
| 15:40-16:00 |
Q&A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 16:00-16:12 |
Percutaneous liver tumors ablation: Current indications and evidence |
Eduardo Houghton | University of Buenos Aires, Argentina |
| 16:12-16:24 |
ctDNA Test Application in MRD for Colorectal Cancer |
Gong Chen | Sun Yat-sen University Cancer Center, China |
| 16:24-16:36 |
DSM transarterial chemosaturation vs DEB TACE in liver metastases: Which works best? |
Alex Tang Ah Lak | Subang Jaya Medical Centre, Malaysia |
| 16:36-16:48 |
Chemoembolization in mCRC |
Roberto Iezzi | Università Cattolica del Sacro Cuore, Italy |
| 16:48-17:00 |
DEBIRI combined with HAIC for colorectal cancer liver metastases |
Xu Zhu | Beijing Cancer Hospital, China |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 17:00-17:12 |
The standard and consensus of thermal ablation for thyroid nodules |
Dong Xu | Zhejiang Cancer Hospital, China |
| 17:12-17:24 |
Treating HCC with cryoablation |
Min Woo Lee | Samsung Medical Center, Korea |
| 17:24-17:36 |
Ultrasound guided microwave ablation for adenomyosis of the uterus |
Hui-Xiong Xu | Zhongshan Hospital，Fudan University, China |
| 17:36-17:48 |
Different energy ablation in tumor treatment |
Yue-Yong Xiao | The First Medical Center of Chinese PLA General Hospital, China |
| 17:48-18:00 |
Ultrasound-guided ablation for liver cancer |
Xiao-Yan Xie | First Affiliated Hospital of Sun Yat-sen University, China |
| 18:00-18:10 |
Q ＆ A |
||
M1会议室 Meeting room - M1
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 12:05-12:10 |
Welcome Speech
Gao-Jun Teng
Zhongda Hospital, Southeast University, China
|
||
| 12:10-12:15 |
Welcome Speech
Lisa X. Xu
Shanghai Jiao Tong University, China
|
||
| 12:15-12:30 |
Present Status And Prospect —— Clinical Application Of Multi-mode Thermal Therapy |
Wen-Tao Li | Fudan University Shanghai Cancer Center, China |
| 12:30-12:45 |
Progress And Prospect of Study on Mechanism Of Multi-mode Thermal Immune Therapy |
Ping Liu | Shanghai Jiao Tong University, China |
| 12:45-13:05 |
Review Comments And Interactive Q&A
Xiao-Yi Ding
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China /
Ji-Jin Yang
Changhai Hospital Affiliated to Naval Medical University, China /
Jian-Song Ji
Lishui Municipal Central Hospital, China /
Hai-Bo Shao
The First Affiliated Hospital of China Meical University, China /
Hai-Dong Zhu
Zhongda Hospital, Southeast University, China
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:42 |
RFA for lung meta |
Koichiro Yamakado | Hyogo Medical University, Japan |
| 13:42-13:54 |
Tansarterial chemoembolization for primary lung cancer |
Feng Duan | PLA General Hospital, China |
| 13:54-14:06 |
Pulmonary ablation beyond RFA |
Roberto Iezzi | Università Cattolica del Sacro Cuore, Italy |
| 14:06-14:18 |
Translational research on early diagnosis and early treatment of lung cancer |
Wen-Hua Liang | The First affiliated Hospital of Guangzhou Medical University, China |
| 14:18-14:30 |
Transbronchial microwave ablation of lung tumors: state of the art |
Calvin Sze Hang Ng | Prince of Wales Hospital, Hong Kong, China |
| 14:30-14:42 |
Opportunities and challenges of robotic surgical systems after downstaging and conversion in the era of immunotherapy |
Jian Hu | The First Affiliated Hospital Zhejiang University, China |
| 14:42-14:54 |
Advances of immunotherapy for lung cancer |
Jie Wang | Cancer Hospital Chinese Academy of Medical Sciences, China |
| 14:54-15:15 |
Q ＆ A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:30-15:42 |
Progress in surgical management of intrahepatic cholangiocarcinoma |
Feng Shen | Third Affiliated Hospital of Naval Medical University (Shanghai Oriental Hepatobiliary Surgery Hospital), China |
| 15:42-15:54 |
Balloon-occlusion for liver embolotherapy: Is there a benefit over traditional microcatheters? |
David C. Madoff | Yale School of Medicine, USA |
| 15:54-16:06 |
Surgical cure and functional preservation for colorectal cancer patients ----the procedures and scientific evidence for LISH |
Ke-Feng Ding | The Second Affiliated Hospital of Zhejiang University School of Medicine, China |
| 16:06-16:18 |
Modified BRTO procedures for portal hypertension |
Hyun Ki Yoon | Asan Medical Center, University of Ulsan College of Medicine, Korea |
| 16:18-16:30 |
Needs assessment of next generation embolics used in oncology |
David M. Liu | Vancouver General Hospital, Canada |
| 16:30-16:42 |
Hepatic plexus nerve block for liver ablation |
Edward W. Lee | David Geffen School of Medicine at UCLA, USA |
| 16:42-16:54 |
Advances of systemic therapy for colorectal cancer with liver metastasis |
Zhi-Yu Chen | Fudan University Shanghai Cancer Center, China |
| 16:54-17:06 |
PTBD for obstructing tumors of the pancreas and bile duct |
Manuel Zeledón | University of Costa Rica, Costa Rica |
| 17:06-17:18 |
Metastastic Deficient Mismatch Repair Colorectal Cancer：From palliative to cure through systemic therapy |
Yan-Hong Deng | The Sixth Affiliated Hospital of Sun Yat-sen University, China |
| 17:18-17:30 |
Techniques and status of hepatic arterial infusion chemotherapy in cholangiocarcinoma |
Xiao-Dong Wang | Beijing Cancer Hospital, China |
| 17:30-17:40 |
Q ＆ A |
||
M2会议室 Meeting Room - M2
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 12:10-12:15 |
致辞
滕皋军
东南大学附属中大医院
|
||
| 12:15-12:30 |
洛铂在肿瘤介入中的临床研究 |
高钦宗 | 北京大学肿瘤医院 |
| 12:30-12:40 |
讨论 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:15-15:30 |
The intersection and integration of medicine and design |
Ning-Hui Hao | Central Academy of Fine Arts, China |
| 15:30-15:35 |
Editor-in-Chief remarks
Gao-Jun Teng
Zhongda Hospital, Southeast University, China
|
||
| 15:35-15:40 |
Certificate Presentation for Guest Editors and Editorial Board Members |
||
| 15:40-15:50 |
Opening speech for Special Issue on Oncology
Xiaoming Yang
University of Washington School of Medicine, USA /
Wen-Hua Liang
The First affiliated Hospital of Guangzhou Medical University, China
|
||
| 15:50-16:00 |
Comprehensive minimally invasive oncologic, locomotive, and pain intervention for skeletal metastases |
Francis Y. Lee | Yale School of Medicine, USA |
| 16:00-16:12 |
Efficacy of cone-beam computed tomography and vessel-tracking technologies in transarterial chemoembolization for hepatocellular carcinoma |
Shiro Miyayama | Fukuiken Saiseikai Hospital, Japan |
| 16:12-16:22 |
Intraluminal MRI and Interventions: Innovation and Application |
Xiaoming Yang | University of Washington School of Medicine, USA |
| 16:22-16:40 |
New insights on lung cancer early diagnosis and prevention |
Wen-Hua Liang | The First affiliated Hospital of Guangzhou Medical University, China |
| 16:40-16:50 |
Discussion |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 16:50-17:00 |
Molecular subtyping and precision treatment of triple-negative breast cancer |
Yi-Zhou Jiang | Fudan University Shanghai Cancer Center, China |
| 17:00-17:10 |
Artificial Intelligence in Percutaneous Ablation Procedures |
Eduardo Houghton | University of Buenos Aires, Argentina |
| 17:10-17:20 |
The treatment and clinical application of bronchial arterial chemoembolization（BACE）in inoperable lung cancer patients |
Jian-Song Ji | Lishui Municipal Central Hospital, China |
| 17:20-17:30 |
Abernethy malformation: interventional treatment vs surgery |
Feng Duan | PLA General Hospital, China |
| 17:30-17:50 |
Discussion |
||
| 17:50-18:00 |
Summary and closing speech |
Xiao-Long Qi | Zhongda Hospital Southeast University, China |
M5会议室 Meeting Room - M5
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:35 |
致辞 |
||
| 13:35-13:40 |
《穿云复攀登，聚爱耀长生》 ——CARES-310研究数据更新发布仪式 |
||
| 13:40-14:00 |
2024 ASCO 肝癌治疗研究热点 |
孙惠川 | 复旦大学附属中山医院 |
| 14:00-14:15 |
大咖论道 |
||
| 14:15-14:35 |
肝癌综合治疗研究进展 |
王忠敏 | 上海交通大学医学院附属瑞金医院 |
| 14:35-14:50 |
大咖论道 |
||
| 14:50-15:05 |
TED演讲：规范化的多学科诊疗模式分享 |
于海鹏 | 天津市肿瘤医院（天津医科大学肿瘤医院） |
| 15:05-15:20 |
大咖论道 |
||
| 15:20-15:35 |
TED演讲：规范化的多学科诊疗模式分享 |
成远 | 中国人民解放军东部战区总医院 |
| 15:35-15:50 |
大咖论道 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 16:00-16:10 |
领导致辞 |
||
| 16:10-16:25 |
介入模拟示范项目探讨 |
吕建平 | 广州市第一人民医院 |
| 16:25-16:50 |
“AI+XR” Empowered Endovascular Treatment of Intracranial Aneurysms |
司伟鑫 | 中国科学院深圳先进技术研究院 |
| 16:50-17:30 |
开放式讨论： 1.模拟虚拟技术在介入领域课程体系建设相关团体标准的筹备工作 2.模拟虚拟、人工智能等技术在介入领域的科研转化与应用 3.2024年11月专委会学术年会介入方向分论坛的筹备工作 |
||
2024-06-08 星期六
EII 厅 Exhibition Area - II
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:12 |
Role of prostate artery embolization for prostate cancer |
Justin J. Guan | Cleveland Clinic, USA |
| 08:12-08:24 |
The utilization of algorithm for the early detection of HCC |
Jia-Yun Liu | Xijing Hospital, China |
| 08:24-08:36 |
Next gen of Y90 devices and emerging clinical data on horizon |
Zhong Qian | Louisiana State University, USA |
| 08:36-08:48 |
Biomaterials and nanomedicine to assist interventional cancer therapies |
Zhuang Liu | Soochow University, China |
| 08:48-09:00 |
Challenge of Car-T therapy for advanced ovarian cancer: From bench to bed |
Yang Shen | Zhongda Hospital, Southeast University, China |
| 09:00-09:12 |
Gd-EOB-DTPA with MRI-guided microwave ablation for very early stage HCC |
Cheng-Li Li | Shandong Provincial Hospital Affiliated to Shandong First Medical University, China |
| 09:12-09:30 |
Q ＆ A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:30-09:42 |
Diet and Drug Resistance in Liver Cancer |
Jian-Ping Guo | First Affiliated Hospital of Sun Yat-sen University, China |
| 09:42-09:54 |
Ethanol embolization/sclerotherapy for benign lesions |
Lixin Su | The Ninth People's Hospital affiliated to Shanghai Jiao Tong University |
| 09:54-10:06 |
Management of portal hypertension in patients with HCC |
Xue-Feng Luo | West China Hospital, Sichuan University, China |
| 10:06-10:18 |
Developments in gastroduodenal stent technology |
Ho-Young Song | Asan Medical Center, University of Ulsan College of Medicine, Affiliated Cancer Hospital of Zhengzhou University, China |
| 10:18-10:30 |
Effect of dendritic cells (DC) - Lymphokine-Activated killer cells (LAKs) in patients with anaplastic thyroid carcinoma combined with first-line treatment |
George Loladze | Cancer Research Center of Georgia |
| 10:30-10:42 |
Targeting intratumoral lactic acidosis (TILA)-TACE for hepatocellular carcinoma |
Kai Jin | The Second Affiliated Hospital of Zhejiang University Medical College, China |
| 10:42-11:00 |
Q ＆ A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:00-11:12 |
New progress of conservative surgery for uterine myoma |
Lan Zhu | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, China. |
| 11:12-11:24 |
MR guided focused ultrasound ablation for uterine fibroids and adenomyosis |
Han Wang | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, China |
| 11:24-11:36 |
Uterine artery embolization for uterine fibroids |
Yong Jin | The Second Affiliated Hospital of Soochow University, China |
| 11:36-11:48 |
Microwave ablation of uterine fibroids and fertility protection |
Jing Zhang | Chinese PLA General Hospital, China |
| 11:48-12:00 |
Q ＆ A |
||
EIII 厅 Exhibition Area - III
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:12 |
Radioactive seed interventional brachytherapy and ablation |
Jun-Jie Wang | Peking University Third Hospital, China |
| 08:12-08:24 |
Personalized dosimetry for Y-90 |
Jon C. Davidson | University Hospitals Cleveland Medical Center, USA |
| 08:24-08:36 |
Precision radio therapy in hepatocellular carcinoma |
Wei-Hu Wang | Beijing Cancer Hospital, China |
| 08:36-08:48 |
The evolution and future of Y-90 therapy in HCC treatment |
Jin Woo Choi | Seoul National University Hospital, Korea |
| 08:48-09:00 |
Using radiotherapy to overcome immunotherapy resistance |
Da-Wei Chen | Shandong Cancer Hospital & Institute, China |
| 09:00-09:30 |
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:12 |
Intraarterial therapies for priming the immune system: Rationale and clinical results |
David C. Madoff | Yale School of Medicine, USA |
| 10:12-10:24 |
Metallic stent placement for malignant ureteral obstruction |
Ji Hoon Shin | Asan Medical Cente, University of Ulsan College of Medicine, Korea |
| 10:24-10:36 |
Tips & tricks in percutaneous liver tumor ablation |
Eduardo Houghton | University of Buenos Aires, Argentina |
| 10:36-10:48 |
Minimally invasive treatments for liver cancer and experience in Macau |
Guang-Hui Luo | Kiang Wu Hospital, Macau, China |
| 10:48-11:00 |
Portal vein embolization |
Sangjoon Park | Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Korea |
| 11:00-11:30 |
Q & A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:30-11:35 |
致辞
颜志平
复旦大学附属中山医院
|
||
| 11:35-11:40 |
全球首款全尺寸可显影载药栓塞微球研发历程 |
张雪非 | 复旦大学高分子材料国家重点实验室 |
| 11:40-11:50 |
超小粒径可显影载药栓塞微球用于原发性肝癌前瞻性，单臂多中心临床试验方案介绍 |
马婧嶔 | 复旦大学附属中山医院 |
| 11:50-12:00 |
精细TACE对栓塞剂的要求 |
彭志毅 | 浙江大学医学院附属第一医院 |
| 12:00-12:05 |
讨论 |
||
M1会议室 Meeting room - M1
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:10 |
Starting your academic career |
Ziv J. Haskal | University of Virginia School of Medicine, USA |
| 08:10-08:30 |
How to get your paper published: Tips from a 15-year editor |
Ziv J. Haskal | University of Virginia School of Medicine, USA |
| 08:30-08:45 |
The write path for doctors: Personal experiences and tips |
Jiaywei Tsauo | Guangdong Provincial People's Hospital, China |
| 08:45-09:00 |
How I mentor Chinese scholars to enhance their writing skills |
Ho-Young Song | Asan Medical Center, University of Ulsan College of Medicine, Affiliated Cancer Hospital of Zhengzhou University, China |
| 09:00-09:45 |
Panel Discussion
Jian Lu
Zhongda Hospital, Southeast University, China /
Chu Hui Zeng
Asan Medical Center, KR/ Zhongda Hospital, Southeast University, China /
Bin-Yan Zhong
The First Affiliated Hospital of Soochow University, China
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:08 |
DEB-TACE for advanced cervical cancer |
Jian-Fei Tu | Lishui Municipal Central Hospital, China |
| 10:08-10:16 |
Uterine artery embolization for adenomyosis: Evaluation of different embolization endpoints |
Yong Jin | The Second Affiliated Hospital of Soochow University, China |
| 10:16-10:24 |
A nomogram predicting venous thromboembolism risk in primary liver cancer patients |
Jing Xiao | Chongqing University Cancer Hospital, China |
| 10:24-10:32 |
Temporary covered stent placement with the aim of spontaneous migration for the treatment of bilioenteric anastomotic stricture |
Kun Yung Kim | Seoul National University Bundang Hospital, Korea |
| 10:32-10:40 |
Y-90 resin microspheres SIRT for liver cancer: A single-center experience |
Lei Zhang | Zhongda Hospiital, Southeast University, China |
| 10:40-10:48 |
Intestinal vascular malformations embolization or resection |
Xian-Chen Huang | The Fourth Affiliated Hospital of Soochow University, China |
| 10:48-11:00 |
Q ＆ A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:00-11:08 |
DEB-TACE combined with thermal ablation versus DEB-TACE alone for large and multinodular HCC: Efficacy and prognostic factors analysis |
Lin Zheng | The Affiliated Cancer Hospital of Zhengzhou University，China |
| 11:08-11:16 |
Multimodal integration of radiology and pathology signatures for distinguishing between aldosterone-producing adenomas and nonfunctional adrenal adenomas |
Zhong-Zhi Jia | Changzhou Second People's Hospital, China |
| 11:16-11:24 |
Modified TACE using low-dose chemotherapy with blank microspheres plus low-dose lenvatinib and microwave ablation for large (≥7 cm) unresectable HCC: The TALEM trial |
Zhi-Mei Huang | Sun Yat-sen University Cancer Center, China |
| 11:24-11:32 |
Hepatic arterial infusion combined with lenvatinib plus tislelizumab for unresectable ICC: A retrospective cohort study |
Bang-Jian Zhou | The First Affiliated Hospital of Soochow University, China |
| 11:32-11:40 |
Calcium phosphate-stabilized vascular disrupting agents CA4P lipiodol emulsion for enhanced chemoembolization |
Lin-Zhu Zhang | Zhongda Hospiital, Southeast University, China |
| 11:40-12:00 |
Q ＆ A |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:00-13:20 |
肝门胆管癌介入微创治疗探索与实践 |
赵中伟 | 丽水市中心医院 |
| 13:20-13:40 |
原发性肝癌---消融治疗 |
叶欣 | 山东第一医科大学第一附属医院（山东省千佛山医院） |
| 13:40-14:00 |
原发性肝癌---粒子植入 |
朱光宇 | 东南大学附属中大医院 |
| 14:00-14:20 |
经桡肝癌栓塞 |
张雯 | 复旦大学附属中山医院 |
| 14:20-14:40 |
讨论 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:00-15:20 |
“靶免时代”肝细胞癌局部治疗何去何从 |
李庆东 | 重庆大学附属肿瘤医院 |
| 15:20-15:40 |
提升HCC TACE疗效---肝癌精细TACE之我见 |
尹国文 | 江苏省肿瘤医院 |
| 15:40-16:00 |
原发性肝癌MDT---临床实践 |
郑家平 | 浙江省肿瘤医院 |
| 16:00-16:20 |
阿伐曲泊帕在肝癌介入诊疗中的价值 |
朱海东 | 东南大学附属中大医院 |
| 16:20-16:40 |
讨论 |
||
M2会议室 Meeting Room - M2
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:05 |
Opening Remarks
Gao-Jun Teng
Zhongda Hospital, Southeast University, China
|
||
| 10:05-10:25 |
Pushing the Envelope for Surgical Management of Advanced Hepatocellular Carcinoma |
Junichi Shindoh | Toranomon Hospital Tokyo Japan, Japan |
| 10:25-10:45 |
2024 ASCO new progress of liver cancer research |
Lian-Xin Liu | The First Affiliated Hospital of University of Science and Technology of China, China |
| 10:45-11:05 |
Panel Discussion
Guang-Shao Cao
Henan Provincial Peoples Hospital, China /
Qi Ling
The First Affiliated Hospital, Zhejiang University School of Medicine, China /
Ji-Zhou Wang
The First Affiliated Hospital of University of Science and Technology of China, China
|
||
| 11:05-11:25 |
Real-world data for Ate/Bev in unresectable HCC |
Hong Jae Chon | CHA Bundang Medical Center, CHA University, Korea |
| 11:25-11:45 |
Emerging immunotherapy for HCC: the end of beginning |
Qiang Gao | Zhongshan Hospital Fudan University, China |
| 11:45-12:05 |
Panel discussion
Xue-Feng Luo
West China Hospital, Sichuan University, China /
Jun Luo
Zhejiang Cancer Hospital, China /
Jian-Jun Han
Shandong Cancer Hospital, China
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:00-15:05 |
主席致辞
滕皋军
东南大学附属中大医院
|
||
| 15:05-15:15 |
"一项比较精细超选择TACE与非精细超选择TACE治疗肝细胞癌 有效性的全国多中心真实世界研究（CHANCE2403）" |
仲斌演 | 苏州大学附属第一医院 |
| 15:15-15:25 |
方案讨论 |
||
| 15:25-15:35 |
"TACE+消融系列研究 1.《TACE+消融针对BCLC-A期肝癌多中心真实世界研究》 2.《TACE+消融针对BCLC-B期肝癌多中心真实世界研究》 3.《TACE+消融针对肝内高危区域肝癌病灶多中心真实世界研究》" |
王健 | 北京大学第一医院 |
| 15:35-15:45 |
方案讨论 |
||
| 15:45-15:55 |
CTACE/DTACE+HAIC对比HAIC联合系统治疗的真实世界研究（CHANCE2404） |
刘宝将 | 北京大学肿瘤医院 |
| 15:55-16:05 |
方案讨论 |
||
| 16:05-16:15 |
BACE联合静脉化疗用于一线经免疫治疗失败的晚期NSCLC的疗效与安全性：一项前瞻性、多中心、非干预性临床研究（CHANCE2406） |
涂建飞 | 丽水市中心医院 |
| 16:15-16:25 |
方案讨论 |
||
| 16:25-16:35 |
肝细胞癌 TACE 后肝脓肿形成的预测及预后 分析:一项回顾性多中心巢式病例对照研究（CHANCE2407） |
畅智慧 | 中国医科大学附属盛京医院 |
| 16:35-16:45 |
方案讨论 |
||
| 16:45-16:55 |
"序贯对比同期TACE联合PD-1/PDL1抑制剂及抗血管生成药物治疗肝细胞癌的全国多中心真实世界研究（CHANCE2401） " |
陈建建 | 东南大学附属中大医院 |
| 16:55-17:05 |
方案讨论 |
||
| 17:05-17:15 |
讨论：如何共创以CHANCE为背景的科研新生态 |
||
| 17:15-17:20 |
会议总结
滕皋军
东南大学附属中大医院
|
||
M4会议室 Meeing Room-M4
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:05 |
院士致辞
滕皋军
东南大学附属中大医院
|
||
| 08:05-08:10 |
执行主席致辞 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:10-08:30 |
介入联合系统治疗在中晚期肝癌的探索 |
赵明 | 中山大学肿瘤防治中心 |
| 08:30-08:50 |
晚期胆道肿瘤治疗策略探讨 |
赵一鸣 | 复旦大学附属肿瘤医院 |
| 08:50-09:00 |
巅峰对话 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:00-09:20 |
肝癌围术期药物治疗研究进展 |
胡育斌 | 福建省肿瘤医院 |
| 09:20-09:40 |
高复发风险肝癌患者术后辅助治疗策略探索 |
白旭明 | 苏州大学附属第二医院 |
| 09:40-09:50 |
巅峰对话 |
||
| 09:50-10:00 |
大会总结 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:10 |
开场致辞 |
||
| 10:10-10:25 |
肝癌精细TACE概述 |
王松 | 青岛大学附属医院 |
| 10:25-10:30 |
讨论 |
||
| 10:30-10:50 |
DSA未来技术汇报/国产DSA的创新汇报 |
||
| 10:50-11:10 |
联影DSA产医结合新技术的探索与未来 |
颜志平 | 复旦大学附属中山医院 |
| 11:10-11:30 |
讨论 |
||
| 11:30-11:45 |
DSA发展趋势与未来 |
韩新巍 | 郑州大学第一附属医院 |
| 11:45-11:50 |
总结
王忠敏
上海交通大学医学院附属瑞金医院
|
||
M5会议室 Meeting Room - M5
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:05 |
院士致辞
滕皋军
东南大学附属中大医院
|
||
| 08:05-08:10 |
主席致辞 |
||
| 08:10-08:30 |
双特异性抗体为基础联合方案在肝癌全程化管理中的研究进展和愿景 |
许丽霞 | 中山大学附属第一医院 |
| 08:30-08:45 |
大咖论道 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:45-09:05 |
如何选刊、投稿和回复审稿人意见 |
赵剑飞 | NEJM医学前沿 |
| 09:05-09:20 |
大咖论道 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:20-09:40 |
中国之声：卡度尼利单抗研究快闪秀 |
吕明 | 山东大学齐鲁医院 |
| 09:40-09:55 |
大咖论道 |
||
| 09:55-10:00 |
会议总结
滕皋军
东南大学附属中大医院
|
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:10 |
主席致辞 |
||
| 10:10-10:30 |
《原发性肝癌诊疗指南（2024年版）》解读 |
杨树法 | 新疆医科大学附属肿瘤医院 |
| 10:30-10:35 |
讨论 |
||
| 10:35-10:55 |
《中国肝细胞癌TACE治疗临床实践指南（2023版）》解读 |
吕维富 | 中国科学技术大学附属第一医院（安徽省立医院） |
| 10:55-11:00 |
讨论 |
||
| 11:00-11:20 |
无限探索 瑞启新机-瑞戈非尼在肝胆肿瘤诊疗领域的创新与探索 |
王松 | 青岛大学附属医院 |
| 11:20-11:25 |
讨论 |
||
| 11:25-11:45 |
后线治疗 无限可能-靶向免疫时代中晚期HCC二线治疗策略探讨 |
朱康顺 | 广州医科大学附属第二医院 |
| 11:45-11:50 |
讨论 |
||
| 11:50-12:00 |
会议总结 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:00-13:20 |
原发性肝癌诊疗指南2024版---外科治疗更新要点 |
刘连新 | 中国科学技术大学附属第一医院（安徽省立医院） |
| 13:20-13:30 |
讨论 |
||
| 13:30-13:50 |
原发性肝癌诊疗指南2024版---介入治疗更新要点 |
刘嵘 | 复旦大学附属中山医院 |
| 13:50-14:00 |
讨论 |
||
| 14:00-14:20 |
原发性肝癌诊疗指南2024版---系统治疗更新要点 |
赵明 | 中山大学肿瘤防治中心 |
| 14:20-14:30 |
讨论 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 14:40-15:00 |
四川大学华西医院单病种规范诊疗中心模式经验分享 |
吴泓 | 四川大学华西医院 |
| 15:00-15:20 |
原发性肝癌三级预防及抗病毒全程管理 |
南月敏 | 河北医科大学第三医院 |
| 15:20-15:40 |
肝癌放疗联合靶免治疗的探讨 |
黎功 | 清华大学附属北京清华长庚医院 |
| 15:40-16:00 |
从指南更新看肝癌的TACE治疗 |
刘瑞宝 | 哈尔滨医科大学附属肿瘤医院 |
| 16:00-16:20 |
讨论 |
||
M9会议室 Meeting room - M9
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:00-09:10 |
主席致辞 |
||
| 09:10-09:25 |
原发性肝癌诊疗指南解读 |
寻琛 | 南京天印山医院 |
| 09:25-09:40 |
“规范化、综合化”推动肝癌介入治疗迈入新阶梯 |
熊斌 | 广州医科大学附属第一医院 |
| 09:40-09:55 |
大咖面对面 |
||
| 09:55-10:00 |
总结 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:03 |
院士致辞
滕皋军
东南大学附属中大医院
|
||
| 10:03-10:10 |
开场致辞 |
||
| 10:10-10:12 |
领导致辞
丁伟
-
|
||
| 10:12-10:15 |
选“泽”三周年 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:15-10:30 |
肝癌MDT发展之路 |
黄明 | 云南省肿瘤医院（昆明医科大学第三附属医院） |
| 10:30-10:40 |
讨论 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:40-10:55 |
首联选泽，更多获益 |
熊斌 | 广州医科大学附属第一医院 |
| 10:55-11:05 |
讨论 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:05-11:20 |
2024 ASCO多纳非尼数据速递 |
尹立楠 | 哈尔滨医科大学附属肿瘤医院 |
| 11:20-11:30 |
讨论 |
||
| 11:30-11:35 |
总结致辞 |
||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:00-13:05 |
院士致辞
滕皋军
东南大学附属中大医院
|
||
| 13:05-13:15 |
主席致辞 |
||
| 13:15-13:35 |
钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识解读 |
朱海东 | 东南大学附属中大医院 |
| 13:35-13:55 |
核医学诊疗一体化在钇90治疗肝部恶性肿瘤中应用 |
王喆 | 西安国际医学中心医院 |
| 13:55-14:10 |
讨论：不同学科如何有效应用钇90治疗技术 |
||
| 14:10-14:25 |
钇90治疗病例MDT - 东南大学附属中大医院MDT团队 |
||
| 14:25-14:40 |
钇90治疗病例MDT - 海军军医大学附属第三医院MDT团队 |
||
| 14:40-14:55 |
讨论：钇90合适的患者人群 |
||
| 14:55-15:00 |
会议总结 |
||